SUBSCRIBE
SUBSCRIBE
News   Business

Vivalis Grants Rights to EBx(R) Cell Line for Testing in Production of Viral Vaccines

June 18, 2008 | 
1 min read

NANTES, FRANCE--(Marketwire - June 18, 2008) - - VIVALIS announced today that it has signed a research license with an animal health company (undisclosed), to evaluate EBx® cell line (EB66) for the production of several viral vaccines.

Alliances Europe
MORE ON THIS TOPIC
Sign outside BioNTech's building in Germany
Breast cancer
BioNTech Builds Case for PD-L1/VEGF Bispecific With Promising Breast Cancer Data
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Podcast
Highlights From ASH, Lilly and Novo’s Manufacturing Boon, Momentum in Neuro, More
December 11, 2024
 · 
1 min read
 · 
Heather McKenzie
Group Of Employees Being Fired By Their Company.
Layoffs
Carisma Therapeutics to Cut 34% of Staff, Reprioritize Pipeline
December 10, 2024
 · 
2 min read
 · 
Angela Gabriel
Correct decision chosing - confused man character standing on the crossroads and looking at signpost with three different directions - conceptual vector illustration
Depression
Relmada Considering ‘Strategic Alternatives’ After Failure of Depression Asset
December 9, 2024
 · 
1 min read
 · 
Heather McKenzie